{"id":"W2566055673","doi":"10.1093/annonc/mdv343.02","title":"Afatinib vs erlotinib as second-line therapy of patients with advanced SCC of the lung following platinum-based chemotherapy: OS analysis from the global phase III trial LUX-Lung 8 (LL8)","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Erlotinib; Clinical endpoint; Lung cancer; Oncology; Gefitinib; Progression-free survival; Chemotherapy; Gastroenterology; Randomized controlled trial; Cancer; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002115096,0.001164597,0.002973558,0.0004783914,0.0002789948,0.00168519,0.000871908,0.001203749,0.00306247],"category_scores_gemma":[0.001795768,0.000360002,0.003985089,0.0005582357,0.0007450762,0.00187405,0.0005478264,0.003517505,0.0006605759],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001219009,"about_ca_system_score_gemma":0.0008666179,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008179835,"about_ca_topic_score_gemma":0.003840573,"domain_scores_codex":[0.9992201,0.0003692507,0.00005177185,0.0001508717,0.00005876588,0.0001491933],"domain_scores_gemma":[0.9989861,0.0002678942,0.0002655944,0.00008975542,0.00005102622,0.0003396778],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8523075,0.00416844,0.01448689,0.001241232,0.006755648,0.0001673344,0.0001657398,0.004976151,0.006661656,0.000332234,0.004885182,0.1038519],"study_design_scores_gemma":[0.6225073,0.2718776,0.07419185,0.0003539257,0.01122696,0.001076643,0.0004267038,0.006651286,0.002961935,0.00186132,0.006701854,0.0001625941],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9880142,0.007132932,0.0002859737,0.0008616424,0.0002291904,0.0002397617,0.001432708,0.00006361819,0.001739917],"genre_scores_gemma":[0.9922608,0.002407309,0.0004186133,0.0007531061,0.0001649712,0.0002269261,0.00224309,0.00003029028,0.001494959],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00306247,"threshold_uncertainty_score":0.01118588,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04202344395474401,"score_gpt":0.4198672195435766,"score_spread":0.3778437755888326,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}